Eandtnews

DelveInsight’s, “Acute Myeloid Leukemia Pipeline Insight 2023” report provides comprehensive insights about 260+ companies and 260+ pipeline drugs in the Acute Myeloid Leukemia pipeline landscape. It covers the pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Acute Myeloid Leukemia Pipeline Report

• DelveInsight’s Acute Myeloid Leukemia pipeline report depicts a robust space with 260+ active players working to develop 260+ pipeline therapies for Acute Myeloid Leukemia treatment.

• The leading Acute Myeloid Leukemia Companies include Rafael Pharmaceuticals, Moleculin Biotech, BioSight, Abbvie, Jazz Pharmaceuticals, Amgen, AstraZeneca, Menarini Group, Polaris Group, Innovent Biologics, Helsinn Healthcare, Actinium Pharmaceuticals, Arog Pharmaceuticals, BerGenBio, and many others.

• Promising Acute Myeloid Leukemia Pipeline Therapies in various stages of development include OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, Azacitidine, Venetoclax, clofarabine, PLX3397, Gilteritinib, Guadecitabine, and others.

• The Acute Myeloid Leukemia companies and academics are working to assess challenges and seek opportunities that could influence R&D Acute Myeloid Leukaemia. The Acute Myeloid Leukemia emerging therapies under development are focused on novel approaches to treat/improve Acute Myeloid Leukaemia.

Request a sample and discover the recent breakthroughs happening in the Acute Myeloid Leukemia Pipeline landscape @ Acute Myeloid Leukemia Pipeline Outlook

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases. It is characterized by clonal expansion of immature “blast cells” in the peripheral blood and bone marrow resulting in ineffective erythropoiesis and bone marrow failure. With recent advancements in the management guidelines, the cure rates have increased up to 15% in patients older than 60 years and about 40% in patients below 60 years of age.

Recent Developmental Activities in the Acute Myeloid Leukemia Treatment Landscape

• In January 2021 Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML).

• In January 2022, Astex Pharmaceuticals, Inc. announced that the European Commission (EC) has granted orphan-drug designation (ODD) to the oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML).

For further information, refer to the detailed Acute Myeloid Leukemia Drugs Launch, Acute Myeloid Leukemia Developmental Activities, and Acute Myeloid Leukemia News, click here for Acute Myeloid Leukemia Ongoing Clinical Trial Analysis

Acute Myeloid Leukemia Emerging Drugs Profile

• Omidubicel: Gamida Cell

Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has also received Orphan Drug Designation in the U.S. and EU

• Uproleselan: GlycoMimetics

Uproleselan (GMI-1271) is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with AML cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. Preclinical research points to the drug’s potential role in moving cancerous cells out of the protective environment of the bone marrow where they hide and escape the effects of chemotherapy. In preclinical studies using animal models of AML, the results of which were presented at meetings of the American Society of Hematology (ASH), GMI-1271 was also associated with a reduction of chemotherapy-induced neutropenia and chemotherapy-induced mucositis. Currently, the drug is in Phase III stage of clinical trial evaluation for the treatment of Relapsed/Refractory Acute Myeloid Leukemia

• ALT 803: ImmunityBio

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T cells. ALT 803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Its mechanism of action is direct specific stimulation of CD8+ T cells and NK cells through beta gamma T-cell receptor binding (not alpha) while avoiding T-reg stimulation.     ALT 803 has improved pharmacokinetic properties, longer persistence in lymphoid tissues and enhanced anti-tumor activity compared to native, non-complexed IL-15 in vivo. It is currently being evaluated in Phase II clinical trial to treat AML

• BPX-501: Bellicum Pharmaceuticals

BPX-501 is an adjunct T cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe safety switch. It is designed to provide a safety net to eliminate alloreactive BPX-501 T cells (via administration of activator agent rimiducid) should uncontrollable GvHD or other T-cell mediated complications occur. This enables physicians to more safely perform stem cell transplants by administering BPX-501 engineered T cells to speed immune reconstitution, provide control over viral infections and enhance Graft-versus-leukemic effect without unacceptable GvHD risk. The ongoing BP-004 clinical study of BPX-501 is being conducted at transplant centers in the U.S. and Europe. Concurrently, Bellicum Pharmaceuticals have reduced and expect to continue to reduce the rivo-cel related activities

Acute Myeloid Leukemia Therapeutics Assessment

There are approx. 260+ key companies which are developing the Acute Myeloid Leukaemia therapies. The Acute Myeloid Leukaemia companies which have their Acute Myeloid Leukaemia drug candidates in the most advanced stage, i.e preregistration include Gamida Cell.

Find out more about the Acute Myeloid Leukemia Pipeline Segmentation, Therapeutics Assessment, and Acute Myeloid Leukemia Emerging Drugs @ Acute Myeloid Leukemia Treatment Landscape

Scope of the Acute Myeloid Leukemia Pipeline Report

• Coverage- Global

• Acute Myeloid Leukemia Companies- Rafael Pharmaceuticals, Moleculin Biotech, BioSight, Abbvie, Jazz Pharmaceuticals, Amgen, AstraZeneca, Menarini Group, Polaris Group, Innovent Biologics, Helsinn Healthcare, Actinium Pharmaceuticals, Arog Pharmaceuticals, BerGenBio, and many others.

• Acute Myeloid Leukemia Pipeline Therapies- OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, Azacitidine, Venetoclax, clofarabine, PLX3397, Gilteritinib, Guadecitabine, and others.

• Acute Myeloid Leukemia Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Acute Myeloid Leukemia Pipeline Companies and Therapies, click here @ Acute Myeloid Leukemia Unmet Needs and Analyst Views

Table of Content

1. Introduction
2. Executive Summary
3. Acute Myeloid Leukaemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Myeloid Leukaemia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Omidubicel: Gamida Cell
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase III)
11. Uproleselan: GlycoMimetics
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. ALT 803: ImmunityBio
15. Early Stage Products (Phase I)
16. JNJ-75276617: Janssen Research & Development, LLC
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. AB001: Agastiya Biotech
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Acute Myeloid Leukaemia Key Companies
23. Acute Myeloid Leukaemia Key Products
24. Acute Myeloid Leukaemia- Unmet Needs
25. Acute Myeloid Leukaemia- Market Drivers and Barriers
26. Acute Myeloid Leukaemia- Future Perspectives and Conclusion
27. Acute Myeloid Leukaemia Analyst Views
28. Acute Myeloid Leukaemia Key Companies
29. Appendix

Got Queries? Find out the related information on Acute Myeloid Leukemia Mergers and acquisitions, Acute Myeloid Leukemia Licensing Activities @ Acute Myeloid Leukemia Recent Trends, and Future Perspectives

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services